You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
High-potency nitro antimicrobials for topical treatment of trichomoniasis
SBC: DESIGNMEDIX, INC. Topic: RDESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDDESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Stabilization of Influenza Vaccine by Silica-Coating
SBC: STONESTABLE, INC. Topic: NIAIDThe goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Cognitive Change Battery: An Assessment for Serial Administration
SBC: COGMETRIC LLC Topic: NIAABSTRACT Detecting change in neuropsychological functioning over time is critical for proper diagnosis and management of many neurological psychiatric and psychological conditions It is well documented that most commonly used cognitive assessments produce significant retest effects such as practice and regression to the mean effects Retest effects can cause substantial changes in test score ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers
SBC: NAJIT TECHNOLOGIES INC Topic: NIAIDDESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance
SBC: EXSCIEN CORPORATION Topic: NIDDKDESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Identifying activators of interferon regulatory factors for neuroprotection
SBC: Neuralexo, LLC Topic: 106Abstract Stroke is a leading cause of morbidity and mortality in the United States However less than of patients are eligible for the current approved interventions of tissue plasminogen activator or thrombectomy We seek to develop new therapeutics to reduce the extent of damage and functional impairment resulting from ischemic injury to the brain an area of significant unmet medical need ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Macromolecule Crystallization Screening Results Analysis
SBC: iXpressGenes, Inc. Topic: 100Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense